Microcirculatory Resistance Predicts Allograft Rejection and Cardiac Events After Heart Transplantation. Journal of the American College of Cardiology Ahn, J., Zimmermann, F. M., Gullestad, L., Angeras, O., Karason, K., Russell, K., Lunde, K., Okada, K., Luikart, H., Khush, K. K., Honda, Y., Pijls, N. H., Lee, S. E., Kim, J., Park, S., Solberg, O., Fearon, W. F. 2021; 78 (24): 2425-2435

Abstract

BACKGROUND: Single-center data suggest that the index of microcirculatory resistance (IMR) measured early after heart transplantation predicts subsequent acute rejection.OBJECTIVES: The goal of this study was to validate whether IMR measured early after transplantation can predict subsequent acute rejection and long-term outcome in a large multicenter cohort.METHODS: From 5 international cohorts, 237 patients who underwent IMR measurement early after transplantation were enrolled. The primary outcome was acute allograft rejection (AAR) within 1 year after transplantation. A key secondary outcome was major adverse cardiac events (MACE) (the composite of death, re-transplantation, myocardial infarction, stroke, graft dysfunction, and readmission) at 10 years.RESULTS: IMR was measured at a median of 7weeks (interquartile range: 3-10weeks) post-transplantation. At 1 year, the incidence of AAR was 14.4%. IMR was associated proportionally with the risk of AAR (per increase of 1-U IMR; adjusted hazard ratio [aHR]: 1.04; 95% confidence interval [CI]: 1.02-1.06; p < 0.001). The incidence of AAR in patients with an IMR=18 was 23.8%, whereas the incidence of AAR in those with an IMR<18 was 6.3% (aHR: 3.93; 95%CI: 1.77-8.73; P=0.001). At 10 years, MACE occurred in 86 (36.3%) patients. IMR was significantly associated with the risk of MACE (per increase of 1-U IMR; aHR: 1.02; 95%CI: 1.01-1.04; P=0.005).CONCLUSIONS: IMR measured early after heart transplantation is associated with subsequent AAR at 1 year and clinical events at 10 years. Early IMR measurement after transplantation identifies patients at higher risk and may guide personalized posttransplantation management.

View details for DOI 10.1016/j.jacc.2021.10.009

View details for PubMedID 34886963